Symrise flags profit decline, missed growth targets, and EU probes
Symrise reported profit declines after end-2025 write-downs, missed organic growth and new product targets, and is selling its U.S. terpene unit AmeriTerpenes to Mutares with supply deals intact. EU antitrust probes continue.
Symrise AG (XETR:SY1) reported profit declines after two end-2025 write-downs and missed organic growth and new-product targets. S. terpene unit AmeriTerpenes to Mutares, with supply agreements remaining in place. Symrise said debt remains manageable and that the dividend is covered by cash flow, while EU antitrust probes continue.